Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy-Reference-Cited by-同舟云学术

Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy

Published:2014-02-12 Issue:2 Volume:1 Page:GRHTA.5000182
ISSN:2284-2403
Container-title:Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish
language:en
Short-container-title:Global & Regional Health Technology Assessment

Author:

Martone Nicoletta¹,Lucioni Carlo²,Mazzi Silvio²,Fadda Valeria³

Affiliation:

1. Celgene Italia, Milano - Italy

2. Health Publishing & Services, Milano - Italy

3. Facoltà di Farmacia, Dipartimento di Scienze Farmaceutiche, Università di Firenze, Firenze - Italy

Publisher

Aboutscience Srl

Subject

Health Policy

Link

http://journals.sagepub.com/doi/pdf/10.5301/GRHTA.5000182

Reference64 articles.

1. Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy

2. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis

3. Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions

4. DrummondM.F., SculpherM.J., TorranceG.W. Methods for the Economic Evaluation of Health Care Programmes. Third edition. Oxford: Oxford University Press, 2005: 379.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy;Global and Regional Health Technology Assessment;2023-09-28

2. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma;Leukemia & Lymphoma;2023-05-25

3. Cost–Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy;Journal of Personalized Medicine;2022-06-10

4. Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy;FARMECONOMIA;2022

5. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy;PharmacoEconomics - Open;2021-07-23